Testosterone Replacement Therapy Side Effects and Safety: What the FDA Record Shows

Testosterone Replacement Therapy Side Effects are documented on the FDA prescribing label, and reported separately by patients and doctors to the FDA’s adverse event system. This page sets out what the official record actually says about Testosterone Replacement Therapy: what it is approved to treat, what the label warns about, its recall history, and what the reported side effects are — along with what those figures do and do not mean.

Before you read on. Do not stop taking a prescribed medicine, or change how you take it, because of anything you read here. Talk to the prescriber or pharmacist who knows your medical history first.

Advertisement

What Testosterone Replacement Therapy Is Prescribed For, and Where Testosterone Replacement Therapy Side Effects Come From

According to the FDA label, estosterone gel 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. […]

Two separate official sources describe testosterone replacement therapy side effects. The prescribing label records what was observed in clinical trials, where the drug was compared against a control group. The FDA’s adverse event database records what patients and clinicians have reported since approval, which is a much larger but far less controlled picture. Both appear below, and they answer different questions.

Active ingredient Testosterone
Brand names on this label Testosterone
How it is given transdermal
Boxed warning Yes – see below
Recall records 25
Label last updated 2024-09-30

The FDA Boxed Warning on Testosterone Replacement Therapy

This medicine carries a boxed warning

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )]. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.2 )].

Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.2 ) and Patient Counseling Information ( 17 )].

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE See full prescribing information for complete boxed warning. Virilization has been reported in children who were secondarily exposed to testosterone gel ( 5.2 , 6.2 ). […]

A boxed warning is the most serious warning the FDA requires on a prescription label. It does not mean the medicine should not be used. It means there is a specific risk serious enough that the FDA requires it to appear at the very top of the prescribing information, so that prescribers weigh it deliberately for each patient.

Prescribers see this warning every time they consult the label. If it concerns you, it is a reasonable thing to raise at your next appointment and ask how it applies to your own situation.

Warnings Beyond the Common Testosterone Replacement Therapy Side Effects

The label’s warnings and precautions section describes risks the FDA requires prescribers to weigh. For Testosterone Replacement Therapy it covers: onitor patients with benign prostatic hyperplasia (BPH) for worsening of signs and symptoms of BPH ( 5.1 ) Avoid unintentional exposure of women or children to testosterone gel 1.62%.

Secondary exposure to testosterone can produce signs of virilization. Testosterone gel 1.62% should be discontinued until the cause of virilization is identified ( 5.2 ) Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone products.

Evaluate patients with signs or symptoms consistent with DVT or PE. ( 5.4 ) Some postmarketing studies have shown an increased risk of myocardial infarction and stroke associated with use of testosterone replacement therapy. […]

These are the risks the FDA has judged significant enough to state formally, and they sit apart from the routine testosterone replacement therapy side effects most people ask about. They apply to different patients to very different degrees, which is why the same medicine can be routine for one person and unsuitable for another.

Testosterone Replacement Therapy Side Effects Listed on the FDA Label

The label’s adverse reactions section records what was observed in clinical trials: he most common adverse reaction (incidence ≥ 5%) is an increase in prostate specific antigen (PSA). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Prasco Laboratories at 1-866-525-0688 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Testosterone gel 1.62% was evaluated in a two-phase, 364-day, controlled clinical study. The first phase was a multi-center, randomized, double-blind, parallel-group, placebo-controlled period of 182 days, in which 234 hypogonadal men were treated with testosterone gel 1.62% and 40 received placebo. […]

Trial data is the most reliable source for how common testosterone replacement therapy side effects are, because the people taking the drug were compared against people who were not. A symptom that appeared just as often in the control group is not caused by the medicine.

Reported Testosterone Replacement Therapy Side Effects in the FDA Database

Reported testosterone replacement therapy side effects — and what these numbers do not mean

The FDA’s adverse event database holds 51,927 reports mentioning Testosterone Replacement Therapy, of which 28,081 were classified as serious.

Read those numbers carefully. An adverse event report means somebody told the FDA that something happened to a person taking this medicine. It is not a finding that the medicine caused it. Reports are submitted voluntarily by patients, families, doctors and manufacturers; nobody verifies them; and the same event can be reported more than once.

Report volume tracks how many people take a drug, how new it is, and how much attention it is getting. A widely prescribed medicine will always show more reports than a rarely used one, and reports rise sharply when a drug is in the news or in litigation. A large number here does not mean a drug is dangerous, and a small number does not mean it is safe.

📨 Get Free Mass Tort Guides Alerts

Free · No spam · Unsubscribe anytime

Most frequently reported Reports
Myocardial Infarction 3,712
Pain 2,690
Fatigue 2,597
Deep Vein Thrombosis 2,396
Cerebrovascular Accident 2,389
Blood Testosterone Decreased 2,323
Pulmonary Embolism 2,246
Anxiety 1,877

Source: FDA Adverse Event Reporting System (FAERS), retrieved July 2026. Non-clinical reporting categories such as “off label use” have been excluded from the list above because they describe how a drug was used, not something that happened to a patient.

Who the Label Says Should Take Extra Care

Contraindications. The label states that Testosterone Replacement Therapy should not be used in certain situations: estosterone gel 1.62% is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )].

Testosterone gel 1.62% is contraindicated in women who are pregnant. Testosterone gel 1.62% can cause virilization of the female fetus when administered to a pregnant woman. Pregnant women need to be aware of the potential for transfer of testosterone from men treated with testosterone gel 1.62%. […]

Interactions with other medicines. ndrogens may decrease blood glucose and therefore may decrease insulin requirements in diabetic patients ( 7.1 ) Changes in anticoagulant activity may be seen with androgens. More frequent monitoring of International Normalized Ratio (INR) and prothrombin time is recommended ( 7.2 ) Use of testosterone with adrenocorticotrophic hormone (ACTH) or corticosteroids may result in increased fluid retention. […]

Older adults. 8.5 Geriatric Use There have not been sufficient numbers of geriatric patients involved in controlled clinical studies utilizing testosterone gel 1.62% to determine whether efficacy in those over 65 years of age differs from younger subjects. Of the 234 patients enrolled in the clinical trial utilizing testosterone gel 1.62%, 21 were over 65 years of age. […]

Your pharmacist can check your full medicine list against this in a couple of minutes, including anything bought over the counter, and that check is free.

Testosterone Replacement Therapy Recall History

The FDA enforcement database records 25 recall entries involving Testosterone Replacement Therapy products (17 Class II, 8 Class III). A recall almost always concerns specific manufactured batches rather than the medicine itself, and different manufacturers of the same generic drug have separate recall records.

The FDA classifies recalls by how serious the potential consequence is. Class I means a reasonable probability of serious harm or death; Class II means temporary or reversible harm is possible; Class III means the product breaks a regulation but is unlikely to cause harm.

Date Class Recalling firm Reason
2025-12-10 Class III Teva Pharmaceuticals USA, Inc Defective Container – A defect in the side-seal which allows leakage of product.
2025-04-23 Class II Eugia US LLC cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.
2025-04-02 Class II Strides Pharma, Inc. Presence of foreign substance: Presence of Benzene.
2025-04-02 Class II Strides Pharma, Inc. Presence of foreign substance: Presence of Benzene.
2024-08-28 Class II Teva Pharmaceuticals USA, Inc Superpotent Drug

If a batch you have was recalled, the pharmacy that dispensed it is the fastest way to find out and to get a replacement. Do not simply stop taking a prescribed medicine because a recall notice exists — the recall may not affect your batch, and stopping can carry its own risk.

Is Testosterone Replacement Therapy the Subject of Litigation?

As of the date on this page, we are not tracking consolidated federal litigation over Testosterone Replacement Therapy. Safety questions have been raised about this medicine, and questions being raised is not the same thing as a case being filed or proven.

We monitor federal court filings and FDA safety communications, and this page is updated when the record changes. Our active case pages list the drug and device litigation currently underway.

If You Are Worried About Testosterone Replacement Therapy Side Effects

Concern about testosterone replacement therapy side effects is a good reason to have a conversation, and not a reason to act alone. Do not stop taking a prescribed medicine, or change how you take it, because of anything you read here. Talk to the prescriber or pharmacist who knows your medical history first. Stopping some medicines abruptly carries risks of its own, and your prescriber can tell you whether that applies to yours.

Write down what you have noticed and when it started before the appointment. Not everything that happens while taking a medicine is one of its testosterone replacement therapy side effects, and a specific account — what changed, when, and how often — is what lets a clinician tell the difference.

You can also report a side effect directly to the FDA through MedWatch. Reports from patients are part of how safety signals are detected, and filing one takes a few minutes.

Frequently Asked Questions

What are the most commonly reported testosterone replacement therapy side effects?

In FDA reports, the most frequently mentioned are myocardial infarction, pain, fatigue. The label’s own adverse reactions section, drawn from clinical trials, is the better guide to how common a side effect actually is, because reports to the FDA are not collected in a way that supports rates.

Has Testosterone Replacement Therapy been recalled?

There are 25 recall records for Testosterone Replacement Therapy products, the most recent dated 2025-12-10. Recalls generally affect specific manufactured batches rather than the medicine as a whole. Your pharmacy can tell you whether a batch you have was affected.

Does Testosterone Replacement Therapy have a boxed warning?

Yes. The boxed warning is reproduced above. It is the most serious warning the FDA requires, and it exists so that prescribers weigh a specific risk for each patient rather than overlooking it.

Do the FDA report numbers tell me how common these testosterone replacement therapy side effects are?

No. Reports are unverified, anyone can file one, and the total mostly reflects how many people take the medicine and how much attention it is getting. A high count is not evidence of danger, and a low one is not evidence of safety. Clinical trial data on the label is the source that supports rates.

Where can I check testosterone replacement therapy side effects for the exact product I have?

DailyMed holds the current FDA label for every marketed product, searchable by the name on your packaging. Different manufacturers and formulations of the same medicine can have slightly different labels, so checking the one you actually have is worth the two minutes.

Official Sources

Related Guides

Going through divorce too? Compare state laws at Divorce Help Guide. Affected by a recalled drug as a Medicare patient? See Medicare Cover Guide. Just diagnosed with a serious illness? Compare life insurance at Life Insure Guide. PFAS in your water? Check homeowners coverage at Home Insure Guide.